

11-25-05

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Alister Campbell et al.

Serial No.:

10/511,506

Case No.: T1574P

US Nat'l Filing Date:

October 15, 2004

Int'l Appl'n No.

PCT/GB03/01771

Int'l Filing Date:

April 24, 2003

For:

ALKYNYL-SUBSTITUTED SPIROCYCLIC SULFAMIDES

FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Commissioner for Patents P.O. BOX 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT <u>UNDER 37 CFR § 1.97</u>

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT EXPRESS MAIL NO.

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail "Post Office to Addressee" on the above date in an envelope addressed

Commissioner for Patents, P. O. Box 1450. Alexandria, Virginia 22313-1450

MAILED BY DATE

Int'l Appl'n No.:

Case No.:

PCT/GB03/01771 T1574P

Case N

2

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

John C. Todaro, Reg. No. 36,036

Attorney for Applicant

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-0125

Date: November 23, 2005

	Substitute for form 1449A/PTO			COMPLETE IF KNOWN		
	INFORMATION DIS	CLOSURE	Application Number	10/511,506		
K	P E STATEMENT BY AF	DDI ICANT	Filing Date	October 15, 2004		
/ [1	FLICANI	First Named Inventor	Alister Campbell et at.		
NO	N 2 3 2005 E		Group Art Unit	1614		
VEX.	(use as many sneets as r	iecessary)	Examiner Name	To Be Assigned		
Si	neet 1 of	2	Attorney Docket Number	T1574P		

			U.S. PA	ATENT DOCUMENTS	
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	A	3,406,184		M.S. Raasch	10/15/1968
	В	3,715,362		S. Dominianni	02/06/1973
	С	5,703,129		Felsenstein et al.	12/30/1997
	D	US 2004/0029862		Belanger et al.	02/12/2004
•			_		
}					
				·	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Office Number		ent Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	A		WO 98/38156		Takeda Chemical Industries	09/03/1998
Examin Signatu	er re				Date Considered	•

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substi	Substitute for form 1449B/PTO			COMPLETE IF KNOWN			
INI	EQRMATION	DIS	CLOSURE	Application Number	10/511,506		
QIP	ATEMENT BY	7 A TD		Filing Date	October 15, 2004		
	A LEMENT BY	AP	PLICANI	First Named Inventor	Alister Campbell et at.		
(use as many sheets as necessary)				Group Art Unit	1614		
SATENO	use as metry sheets	s as n	ecessary)	Examiner Name	To Be Assigned		
Sheet	2	of	2	Attorney Docket Number	T1574P		

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.					
	A	J. E. Franz, et al.: Journal of Organic Chemistry, vol. 29, no. 10, October 1964, pages 2922-2927					
	В	R. Huisgen, et al.: Chemische Berichte, vol. 98, no. 12, December 1965, pages 3992-4013					
	С	S. Itsuno, et al.: Journal of the Chemical Society, Perkin Transactions 1, no. 10, 15 July 1999 pages 2011-2016					
	D	M. Narisada, et al.: Journal of Medicinal Chemistry, vol. 31, no. 9, September 1988, pages 1847-1854					
•	E	K. B. Sharpless, et al.: Journal of Organic Chemistry, vol. 41, no. 1, 9 January 1976, pages 176-177					
3	F	Y. Yamaguchi, et al.: Xenobiotica, vol. 26, no. 6, June 1996, pages 613-626					
	G	L. H. Zalkow, et al.: Journal of the American Chemical Society, vo. 86, no. 19, 5 October 1964					
	Н	L. H. Zalkow, et al.: Journal of Organic Chemistry, vol. 28, no. 12, December 1963, pages 3303-3309					
_							
	L						

Examiner Signature	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.